Please login to the form below
Abraxane
This page shows the latest Abraxane news and features for those working in and with pharma, biotech and healthcare.
Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer
11.1 months compared to 9.2 months for patients treated with the standard regimen of Bristol-Myers Squibb’s Abraxane (nab-paclitaxel) plus gemcitabine.
Latest news
-
Tecentriq combo fails in advanced triple negative breast cancer
Tecentriq has already been approved in combination with Abraxane (nab-paclitaxel), after demonstrating a statistically significant PFS benefit and clinically meaningful improvements in OS for people with metastatic TNBC whose tumours
-
FDA sets June decision date for Tecentriq monotherapy in NSCLC
In December, Roche also won approval for Tecentriq in combination with a chemotherapy regimen of Abraxane and carboplatin in NSCLC patients, whose cancer has metastasized and does not have EGFR or
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
The actual progression-free survival (PFS) numbers for KEYNOTE-355 – which compared Keytruda plus Bristol-Myers Squibb/Celgene’s Abraxane (nab-paclitaxel), paclitaxel or gemcitabine/carboplatin to the chemo drugs given ... plus Abraxane.
-
NICE turns down Roche’s Tecentriq for triple-negative breast cancer
Tecentriq has been approved by the EMA for use in patients ineligible for surgery alongside Celgene’s Abraxane (nab-paclitaxel), and NICE estimates that around 600 of the 2, 000 women
-
Tecentriq approved in Europe for triple negative breast cancer
The scale of those revenues will very much depend on how far Roche can extend its use beyond this first setting in combination with Abraxane. ... Oncologists say there is still debate about what the best chemotherapy backbone is for anti-PD-L1 treatment
More from news
Approximately 14 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
-
Chinese biotech’s global ambitions
Meanwhile, BeiGene entered into a strategic global collaboration with Celgene in 2017, gaining the rights to Celgene’s Abraxane Revlimid and Vidaza in China, while Celgene gained an option to market
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Marketing strategy in complex environments
cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
